MBX Biosciences, Inc.
MBXUnited States
8 filed reports · 190 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
8 reports · Sep 2024 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 6 | 943 | Sep 2024 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 2 | 743 | Dec 2024 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 6, 2026 | 287 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 7, 2026 | 178 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 12, 2026 | 487 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 6, 2025 | 173 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 7, 2025 | 109 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 12, 2025 | 116 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 17, 2025 | 256 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 7, 2024 | 80 | Open |
Financial data
190 concepts · 1,686 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial190 concepts · 1,686 facts · Mar 2023 to Aug 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value17 · Mar 2023 to Jun 2026
- Net income loss17 · Mar 2023 to Jun 2026
- Other comprehensive income loss net of tax portion attributable to parent17 · Mar 2023 to Jun 2026
- Stockholders equity (US GAAP)17 · Mar 2023 to Jun 2026
- Stock issued during period value stock options exercised17 · Mar 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations15 · Sep 2023 to Jun 2026
- Comprehensive income net of tax15 · Sep 2023 to Jun 2026
- Depreciation15 · Sep 2023 to Jun 2026
- General and administrative expense (US GAAP)15 · Sep 2023 to Jun 2026
- Interest and other income15 · Sep 2023 to Jun 2026
- Net income loss available to common stockholders basic15 · Sep 2023 to Jun 2026
- Operating expenses (US GAAP)15 · Sep 2023 to Jun 2026
- Operating income loss15 · Sep 2023 to Jun 2026
- Other comprehensive income unrealized holding gain loss on securities arising during period net of tax15 · Sep 2023 to Jun 2026
- Research and development expense15 · Sep 2023 to Jun 2026
- Accretion amortization of discounts and premiums investments14 · Dec 2023 to Jun 2026
- Capital expenditures incurred but not yet paid14 · Dec 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect14 · Dec 2023 to Jun 2026
- Increase decrease in accounts payable14 · Dec 2023 to Jun 2026
- Increase decrease in accrued liabilities14 · Dec 2023 to Jun 2026
- Increase decrease in operating lease liability14 · Dec 2023 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets14 · Dec 2023 to Jun 2026
- Net cash provided by used in financing activities14 · Dec 2023 to Jun 2026
- Net cash provided by used in investing activities14 · Dec 2023 to Jun 2026
Segments
Figures broken down by business line, region, product or another axis the company reports on.
No segment breakdowns.
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.